<DOC>
	<DOC>NCT01271166</DOC>
	<brief_summary>This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of Glivec速 in combination with mFOLFOX-Avastin速. Patients will be enrolled into each dose level in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to the toxicities observed. Once the MTD has been determined the dose level below will be re-opened and extra patients, to a total of 15, will be enrolled.</brief_summary>
	<brief_title>Glivec速 Plus m-FOLFOX Avastin速 in Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirmed, locally advanced, recurrent or metastatic colorectal cancer ECOG 0 or 1 Measurable disease Prior first line therapy for advanced disease Significant bulk of metastatic disease or rapid progression If prior adjuvant therapy, relapse within 6 months of a 5FU based regimen or 12 months of an oxaliplatin based regimen Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Colorectal,</keyword>
	<keyword>Cancer</keyword>
</DOC>